ST PHARM CO., LTD.

As of June 30, 2026, ST PHARM CO., LTD. carries a market capitalization of 2.75T, placing it among publicly traded companies globally. Its enterprise value stands at 2.66T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ST PHARM CO., LTD.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, ST PHARM CO., LTD. has 20.84M shares outstanding.

As of June 30, 2026, ST PHARM CO., LTD. trades at a trailing price-to-earnings ratio of 35.71. The price-to-sales ratio is 7.10, and the price-to-book ratio stands at 4.38.

As of June 30, 2026, ST PHARM CO., LTD. trades at an EV/EBITDA multiple of 25.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 37.54 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ST PHARM CO., LTD. trades at an EV/FCF ratio of 34.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.66T versus a market cap of 2.75T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ST PHARM CO., LTD. maintains a current ratio of 2.28, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ST PHARM CO., LTD. posted a return on equity (ROE) of 13.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.72, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.61, useful for judging operating efficiency across full business cycles. The company generates approximately 514.59M in revenue per employee across its workforce of 751.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.29 indicates how many times ST PHARM CO., LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ST PHARM CO., LTD. recorded 9.22B in income tax expense. That works out to an effective tax rate of 10.71, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 86.06B, leaving 76.80B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, ST PHARM CO., LTD.'s stock has declined approximately 0.99% over the past 52 weeks. The 50-day moving average sits at 96,716.00, while the 200-day moving average is 125,519.00.

Over the twelve months ended June 30, 2026, ST PHARM CO., LTD. generated 386.46B in revenue and converted that into 76.80B in net income, yielding earnings per share of 3,698.48. EBITDA reached 104.62B, while operating income came in at 70.82B.

As of June 30, 2026, ST PHARM CO., LTD. holds 170.44B in cash and equivalents against 74.81B in total debt, resulting in a net debt position of 18.93B. Total book value stands at 629.48B, with working capital of 250.90B providing operational flexibility.

ST PHARM CO., LTD. produced 112.63B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -35.53B in capital expenditures, free cash flow totaled 77.10B - equivalent to 3,716.70 per share.

Over the twelve months ended June 30, 2026, ST PHARM CO., LTD. posted a gross margin of 40.15, reflecting its pricing power and cost economics. The operating margin of 18.33 and net profit margin of 19.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ST PHARM CO., LTD. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.35, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ST PHARM CO., LTD. shareholders.

As of June 30, 2026, ST PHARM CO., LTD. has an Altman Z-Score of 9.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.